Postmenopausal women who were overweight or obese and lost at least 5% of their body weight had a measurable reduction in markers of inflammation, according to a study published in the May 1, 2012 edition of Cancer Research, a journal of the American Association for Cancer Research (AACR).
?Both obesity and inflammation have been shown to be related to several types of cancer, and this study shows that if you reduce weight, you can reduce inflammation as well,? said Anne McTiernan, M.D., Ph.D., director of the Prevention Center at the Fred Hutchinson Cancer Research Centerin Seattle, WA (USA).
Women in the trial who were assigned to a weight loss intervention had a goal of 10% weight reduction during the course of one year achieved through a diet intervention with or without aerobic exercise. Commenting of the weight reduction goal, McTiernan said “So this program was highly achievable and reproducible. We are not talking about drastic weight loss.”
The researchers measured levels of C-reactive protein, serum amyloid A, interleukin-6, leukocyte and neutrophil in 439 women. At the end of one year, C-reactive protein reduced by 36.1% in the diet-alone group and by 41.7% in the diet and exercise group. Interleukin-6 decreased by 23.1% in the diet group and 24.3% in the diet and exercise group.
Greater reduction
McTiernan and colleagues found a mild dose response, as there were greater reductions in these measures among women who lost at least 5% of their body weight. They also found that exercise alone, without a dietary weight loss component, had little effect on inflammation markers. ?This study adds to the growing understanding we have about the link between obesity and cancer, and it appears we can affect inflammation directly through nonpharmaceutical means,? McTiernan said.
For more information:
Imayama I, Ulrich CM, Alfano CM, Wang C, Xiao L, Wener MH, et al. Effects of a Caloric Restriction Weight Loss Diet and Exercise on Inflammatory Biomarkers in Overweight/Obese Postmenopausal Women: A Randomized Controlled Trial.Cancer Res; 72(9); 2314?26.
